Long GV - Search Results

1

New combinations and immunotherapies for melanoma: latest evidence and clinical utility.

Menzies AM, Long GV. Menzies AM, et al. Among authors: long gv. Ther Adv Med Oncol. 2013 Sep;5(5):278-85. doi: 10.1177/1758834013499637. Ther Adv Med Oncol. 2013. PMID: 23997828 Free PMC article.

2

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Long GV, et al. J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343559

3

Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care.

Scolyer RA, Long GV, Thompson JF. Scolyer RA, et al. Among authors: long gv. Mol Oncol. 2011 Apr;5(2):124-36. doi: 10.1016/j.molonc.2011.03.002. Epub 2011 Mar 21. Mol Oncol. 2011. PMID: 21482206 Free PMC article. Review.

4

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Wilmott JS, et al. Among authors: long gv. Clin Cancer Res. 2012 Mar 1;18(5):1386-94. doi: 10.1158/1078-0432.CCR-11-2479. Epub 2011 Dec 12. Clin Cancer Res. 2012. PMID: 22156613

5

Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.

Murali R, Haydu LE, Long GV, Quinn MJ, Saw RP, Shannon K, Spillane AJ, Stretch JR, Kefford RF, Thompson JF, Scolyer RA. Murali R, et al. Among authors: long gv. Ann Surg Oncol. 2012 Jun;19(6):1782-9. doi: 10.1245/s10434-012-2265-y. Epub 2012 Feb 14. Ann Surg Oncol. 2012. PMID: 22350600 Clinical Trial.

6

Treatment of melanoma brain metastases: a new paradigm.

Carlino MS, Fogarty GB, Long GV. Carlino MS, et al. Among authors: long gv. Cancer J. 2012 Mar-Apr;18(2):208-12. doi: 10.1097/PPO.0b013e31824b2890. Cancer J. 2012. PMID: 22453023 Review.

7

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Menzies AM, et al. Among authors: long gv. Clin Cancer Res. 2012 Jun 15;18(12):3242-9. doi: 10.1158/1078-0432.CCR-12-0052. Epub 2012 Apr 24. Clin Cancer Res. 2012. PMID: 22535154

8

Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma.

Murali R, Brown PT, Kefford RF, Scolyer RA, Thompson JF, Atkins MB, Long GV. Murali R, et al. Among authors: long gv. Cancer. 2012 Sep 15;118(18):4519-29. doi: 10.1002/cncr.27693. Epub 2012 Jun 26. Cancer. 2012. PMID: 22736239

9

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.

Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, Long GV, Fernandez-Peñas P. Anforth RM, et al. Among authors: long gv. Br J Dermatol. 2012 Nov;167(5):1153-60. doi: 10.1111/j.1365-2133.2012.11155.x. Epub 2012 Oct 5. Br J Dermatol. 2012. PMID: 22804352 Clinical Trial.

10

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, Scolyer RA, Long GV. Wilmott JS, et al. Among authors: long gv. Mol Cancer Ther. 2012 Dec;11(12):2704-8. doi: 10.1158/1535-7163.MCT-12-0530. Epub 2012 Sep 7. Mol Cancer Ther. 2012. PMID: 22962325

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results